Clinical Trials · NCT00744224
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Amsterdam UMC, location VUmc
- Enrollment
- 8
- Start date
- Feb 2009
- Locations
- 1 site, Netherlands
- Primary endpoint
- To assess whether a single day infusion of the GLP-1 RA exenatide, as compared to placebo, reverses GC-induced impairment of glucose metabolism in healthy males, quantified as glucose tolerance (AUCgluc) during a standardized mixed-meal test